查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1602831

抗真菌药物市场：按感染类型、剂型和治疗适应症分类 - 全球预测 2025-2030

Antifungal Drugs Market by Infection Type (Superficial Fungal Infection, Systemic Fungal infection), Type (Allylamines, Azoles, Echinocandins), Form, Therapeutic Indications - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年抗真菌药物市值为148.9亿美元，预计2024年将达到158亿美元，复合年增长率为6.19%，预计到2030年将达到226.9亿美元。

抗真菌药物市场涵盖了为治疗感染人体各部位的真菌感染疾病而开发的广泛药物类别。这些感染疾病的范围从皮肤和指甲等浅层感染疾病到影响内臟器官的系统性、可能危及生命的疾病。对抗真菌药物的需求主要是由于全球人口增长、都市化以及爱滋病和癌症等免疫力缺乏低下感染疾病的推动，真菌感染发病率不断上升。抗真菌药物用途广泛，从治疗足癣的非处方药到治疗侵袭性曲菌症等严重感染疾病的处方药。主要最终用户包括医院、诊所和家庭护理机构，它们对于这些药物的分配和管理至关重要。

主要市场统计
基准年[2023] 148.9亿美元
预测年份 [2024] 158亿美元
预测年份 [2030] 226.9亿美元
复合年增长率（%） 6.19%

市场成长受到对真菌感染疾病认识的提高、药物配方的进步以及研究经费的增加等因素的影响。此外，医院感染的增加增加了对更有效和快速起效的抗真菌治疗的需求。该公司看到了这个市场的潜在机会，包括开拓新的药物类别、改进的药物输送系统以及针对多重抗药性菌株的标靶治疗。製药业内对研发和策略联盟的持续投资对于利用这些机会至关重要。

然而，市场成长受到抗药性、目前治疗的副作用以及严格的药物核准监管政策的限制。此外，药物开发的高成本和开拓市场所需的大量时间是主要挑战。最佳创新领域包括基因组研究，以了解真菌病原体的抗药性机制以及寻找天然来源的抗真菌化合物。市场充满活力且竞争激烈，学名药製造商的竞争非常激烈，需要具有成本效益的解决方案。投资尖端研究和策略联盟以提高抗真菌功效并减少副作用的公司将在这个不断变化的市场环境中处于有利地位。

市场动态：揭示快速发展的抗真菌药物市场的关键市场洞察

供需的动态交互作用正在改变抗真菌药物市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 全球真菌感染疾病流行
    • 对多种真菌感染疾病的高度认识
    • 政府对抗真菌药物的有利核准
  • 市场限制因素
    • 继续偏好传统抗真菌药物
  • 市场机会
    • 加大研发投入，注重产品创新
    • 抗真菌药物策略联盟和伙伴关係
  • 市场挑战
    • 假药的存在和品牌药品专利到期

波特五力：驾驭抗真菌药物市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解抗真菌药物市场的外部影响

外部宏观环境因素在塑造抗真菌药物市场的表现动态中发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解抗真菌药物市场的竞争格局

抗真菌药物市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV定位矩阵抗真菌药物市场供应商绩效评估

FPNV定位矩阵是评估抗真菌药物市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘抗真菌药物市场的成功之路

抗真菌药物市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 全球真菌感染疾病率增加
      • 对各种真菌感染疾病的意识层级
      • 政府对抗真菌药物的有利核准
    • 抑制因素
      • 传统抗真菌药物仍然是优先考虑的
    • 机会
      • 加大研发投入，注重产品创新
      • 抗真菌药物策略联盟和伙伴关係
    • 任务
      • 假药的存在和品牌药品的专利到期
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

抗真菌药物市场

  • 表层真菌感染疾病
  • 全身性真菌感染疾病

第七章抗真菌药物市场：按类型

  • Allylamines
    • 布替萘芬
    • Naftifine
    • Terbinafine
  • Azole
    • 咪唑
    • 噻唑
    • Voricanazole
  • Echinocandins
    • 阿尼杜拉·芬金
    • Caspofungin
    • Micafungin
  • Polyenes
    • 两性霉素B
    • 念珠菌素
    • 哈霉素
    • 游霉素

抗真菌药物市场：按形式

  • 软膏
  • 粉末
  • 药片

抗真菌药物市场

  • 曲菌症
  • 念珠菌症
  • 皮肤丝状菌症

第十章美洲抗真菌药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太抗真菌药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲抗真菌药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • Astellas Pharma Inc.
  • Bayer HealthCare Pharmaceuticals LLC
  • Becton, Dickinson and Company
  • bioMerieux SA
  • Cadila Pharmaceuticals Limited
  • Cardinal Health, Inc.
  • Cipla, Inc.
  • Enzon Pharmaceuticals, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • Hologic, Inc.
  • Johnson & Johnson
  • Lakewood-Amedex, Inc.
  • Merck KGaA
  • Novartis AG
  • Pfizer, Inc.
  • Quest Diagnostics Incorporated
  • SCYNEXIS, Inc.
  • Sigma-Aldrich, Inc.
  • Sun Pharmaceutical Industries Ltd.
Product Code: MRR-4312A385A460

The Antifungal Drugs Market was valued at USD 14.89 billion in 2023, expected to reach USD 15.80 billion in 2024, and is projected to grow at a CAGR of 6.19%, to USD 22.69 billion by 2030.

The antifungal drugs market is dedicated to the broad category of pharmaceuticals developed to treat fungal infections, which affect various parts of the human body. These infections range from superficial, like skin or nail infections, to systemic and potentially life-threatening diseases affecting internal organs. The necessity for antifungal medications is primarily driven by the rising incidence of fungal infections, spurred by increasing global populations, urbanization, and immunocompromised conditions such as AIDS and cancer. Applications of antifungal drugs are extensive, including over-the-counter treatments for athlete's foot to prescription medications for more severe infections like invasive aspergillosis. Key end-users include hospitals, clinics, and home-care settings, which are crucial to distributing and administering these medications.

KEY MARKET STATISTICS
Base Year [2023] USD 14.89 billion
Estimated Year [2024] USD 15.80 billion
Forecast Year [2030] USD 22.69 billion
CAGR (%) 6.19%

Market growth is influenced by factors such as increased awareness about fungal infections, advancements in drug formulations, and a rise in research funding. Additionally, the incidence of hospital-acquired infections is driving demand for more effective and rapid-acting antifungal treatments. The market sees potential opportunities in the development of novel drug classes, improved drug-delivery systems, and targeted therapies for multidrug-resistant strains. To capitalize on these opportunities, continued investment in R&D and strategic partnerships within the pharmaceutical industry are essential.

However, market growth faces limitations, including drug resistance, adverse side effects of current treatments, and stringent regulatory policies for drug approval. Furthermore, the high cost of drug development and the extensive time required for market introduction present significant challenges. Best areas of innovation include genomic research to understand fungal pathogens' resistance mechanisms and the exploration of naturally derived antifungal compounds. The market is dynamic and competitive, with strong competition from generic drug manufacturers pushing for cost-effective solutions. Businesses that invest in cutting-edge research and strategic collaborations to enhance antifungal efficacy and reduce side effects are poised for advantageous positioning in this evolving market landscape.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Antifungal Drugs Market

The Antifungal Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing prevalence of fungal infection among population worldwide
    • High awareness levels pertaining to myriad fungal infections
    • Favorable government approvals for antifungal drugs
  • Market Restraints
    • Continued preference for conventional antifungal drugs
  • Market Opportunities
    • Increased R&D funding and focus on product innovation
    • Stategic alliances and partnerships for antifungal drugs
  • Market Challenges
    • Presence of counterfeit drugs and patent expiration of branded drugs

Porter's Five Forces: A Strategic Tool for Navigating the Antifungal Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Antifungal Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Antifungal Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Antifungal Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Antifungal Drugs Market

A detailed market share analysis in the Antifungal Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Antifungal Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Antifungal Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Antifungal Drugs Market

A strategic analysis of the Antifungal Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Antifungal Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Astellas Pharma Inc., Bayer HealthCare Pharmaceuticals LLC, Becton, Dickinson and Company, bioMerieux SA, Cadila Pharmaceuticals Limited, Cardinal Health, Inc., Cipla, Inc., Enzon Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., Hologic, Inc., Johnson & Johnson, Lakewood-Amedex, Inc., Merck KGaA, Novartis AG, Pfizer, Inc., Quest Diagnostics Incorporated, SCYNEXIS, Inc., Sigma-Aldrich, Inc., and Sun Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Antifungal Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Infection Type, market is studied across Superficial Fungal Infection and Systemic Fungal infection.
  • Based on Type, market is studied across Allylamines, Azoles, Echinocandins, and Polyenes. The Allylamines is further studied across Butenafine, Naftifine, and Terbinafine. The Azoles is further studied across Imidazoles, Thiazoles, and Voricanazole. The Echinocandins is further studied across Anidulafungin, Caspofungin, and Micafungin. The Polyenes is further studied across Amphotericin B, Candicidin, Hamycin, and Natamycin.
  • Based on Form, market is studied across Ointments, Powder, and Tablets.
  • Based on Therapeutic Indications, market is studied across Aspergillosis, Candidiasis, and Dermatophytosis.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of fungal infection among population worldwide
      • 5.1.1.2. High awareness levels pertaining to myriad fungal infections
      • 5.1.1.3. Favorable government approvals for antifungal drugs
    • 5.1.2. Restraints
      • 5.1.2.1. Continued preference for conventional antifungal drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Increased R&D funding and focus on product innovation
      • 5.1.3.2. Stategic alliances and partnerships for antifungal drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Presence of counterfeit drugs and patent expiration of branded drugs
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Antifungal Drugs Market, by Infection Type

  • 6.1. Introduction
  • 6.2. Superficial Fungal Infection
  • 6.3. Systemic Fungal infection

7. Antifungal Drugs Market, by Type

  • 7.1. Introduction
  • 7.2. Allylamines
    • 7.2.1. Butenafine
    • 7.2.2. Naftifine
    • 7.2.3. Terbinafine
  • 7.3. Azoles
    • 7.3.1. Imidazoles
    • 7.3.2. Thiazoles
    • 7.3.3. Voricanazole
  • 7.4. Echinocandins
    • 7.4.1. Anidulafungin
    • 7.4.2. Caspofungin
    • 7.4.3. Micafungin
  • 7.5. Polyenes
    • 7.5.1. Amphotericin B
    • 7.5.2. Candicidin
    • 7.5.3. Hamycin
    • 7.5.4. Natamycin

8. Antifungal Drugs Market, by Form

  • 8.1. Introduction
  • 8.2. Ointments
  • 8.3. Powder
  • 8.4. Tablets

9. Antifungal Drugs Market, by Therapeutic Indications

  • 9.1. Introduction
  • 9.2. Aspergillosis
  • 9.3. Candidiasis
  • 9.4. Dermatophytosis

10. Americas Antifungal Drugs Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Antifungal Drugs Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Antifungal Drugs Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Astellas Pharma Inc.
  • 3. Bayer HealthCare Pharmaceuticals LLC
  • 4. Becton, Dickinson and Company
  • 5. bioMerieux SA
  • 6. Cadila Pharmaceuticals Limited
  • 7. Cardinal Health, Inc.
  • 8. Cipla, Inc.
  • 9. Enzon Pharmaceuticals, Inc.
  • 10. F. Hoffmann-La Roche Ltd.
  • 11. Gilead Sciences, Inc.
  • 12. Hologic, Inc.
  • 13. Johnson & Johnson
  • 14. Lakewood-Amedex, Inc.
  • 15. Merck KGaA
  • 16. Novartis AG
  • 17. Pfizer, Inc.
  • 18. Quest Diagnostics Incorporated
  • 19. SCYNEXIS, Inc.
  • 20. Sigma-Aldrich, Inc.
  • 21. Sun Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. ANTIFUNGAL DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. ANTIFUNGAL DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS ANTIFUNGAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS ANTIFUNGAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES ANTIFUNGAL DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES ANTIFUNGAL DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. ANTIFUNGAL DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. ANTIFUNGAL DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANTIFUNGAL DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANTIFUNGAL DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY SUPERFICIAL FUNGAL INFECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY SYSTEMIC FUNGAL INFECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY BUTENAFINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY NAFTIFINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY TERBINAFINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY IMIDAZOLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY THIAZOLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY VORICANAZOLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY ANIDULAFUNGIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY CASPOFUNGIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY MICAFUNGIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY AMPHOTERICIN B, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY CANDICIDIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY HAMYCIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY NATAMYCIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY OINTMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY POWDER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY ASPERGILLOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY CANDIDIASIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL ANTIFUNGAL DRUGS MARKET SIZE, BY DERMATOPHYTOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS ANTIFUNGAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. ARGENTINA ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 52. ARGENTINA ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 53. ARGENTINA ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 54. ARGENTINA ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 57. BRAZIL ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. BRAZIL ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. BRAZIL ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 60. BRAZIL ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 61. BRAZIL ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 62. BRAZIL ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 63. BRAZIL ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 64. BRAZIL ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 65. CANADA ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. CANADA ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. CANADA ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 68. CANADA ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 69. CANADA ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 70. CANADA ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 71. CANADA ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 72. CANADA ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 73. MEXICO ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. MEXICO ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. MEXICO ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 76. MEXICO ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 77. MEXICO ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 78. MEXICO ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 79. MEXICO ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 80. MEXICO ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 81. UNITED STATES ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. UNITED STATES ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. UNITED STATES ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 84. UNITED STATES ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 85. UNITED STATES ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 86. UNITED STATES ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 87. UNITED STATES ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 88. UNITED STATES ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 89. UNITED STATES ANTIFUNGAL DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 99. AUSTRALIA ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. AUSTRALIA ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. AUSTRALIA ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 102. AUSTRALIA ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 103. AUSTRALIA ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 104. AUSTRALIA ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 105. AUSTRALIA ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 106. AUSTRALIA ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 107. CHINA ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. CHINA ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. CHINA ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 110. CHINA ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 111. CHINA ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 112. CHINA ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 113. CHINA ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 114. CHINA ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 115. INDIA ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. INDIA ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. INDIA ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 118. INDIA ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 119. INDIA ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 120. INDIA ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 121. INDIA ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 122. INDIA ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 123. INDONESIA ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. INDONESIA ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. INDONESIA ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 126. INDONESIA ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 127. INDONESIA ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 128. INDONESIA ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 129. INDONESIA ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 130. INDONESIA ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 131. JAPAN ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. JAPAN ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. JAPAN ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 134. JAPAN ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 135. JAPAN ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 136. JAPAN ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 137. JAPAN ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 138. JAPAN ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 139. MALAYSIA ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. MALAYSIA ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. MALAYSIA ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 142. MALAYSIA ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 143. MALAYSIA ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 144. MALAYSIA ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 145. MALAYSIA ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 146. MALAYSIA ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 147. PHILIPPINES ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. PHILIPPINES ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. PHILIPPINES ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 150. PHILIPPINES ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 151. PHILIPPINES ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 152. PHILIPPINES ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 153. PHILIPPINES ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 154. PHILIPPINES ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 155. SINGAPORE ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. SINGAPORE ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. SINGAPORE ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 158. SINGAPORE ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 159. SINGAPORE ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 160. SINGAPORE ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 161. SINGAPORE ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 162. SINGAPORE ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH KOREA ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH KOREA ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH KOREA ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH KOREA ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH KOREA ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH KOREA ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH KOREA ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 170. SOUTH KOREA ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 171. TAIWAN ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. TAIWAN ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. TAIWAN ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 174. TAIWAN ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 175. TAIWAN ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 176. TAIWAN ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 177. TAIWAN ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 178. TAIWAN ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 179. THAILAND ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. THAILAND ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. THAILAND ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 182. THAILAND ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 183. THAILAND ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 184. THAILAND ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 185. THAILAND ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 186. THAILAND ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 187. VIETNAM ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. VIETNAM ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. VIETNAM ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 190. VIETNAM ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 191. VIETNAM ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 192. VIETNAM ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 193. VIETNAM ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 194. VIETNAM ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 204. DENMARK ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 205. DENMARK ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 206. DENMARK ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 207. DENMARK ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 208. DENMARK ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 209. DENMARK ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 210. DENMARK ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 211. DENMARK ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 212. EGYPT ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 213. EGYPT ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. EGYPT ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 215. EGYPT ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 216. EGYPT ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 217. EGYPT ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 218. EGYPT ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 219. EGYPT ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 220. FINLAND ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. FINLAND ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 222. FINLAND ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 223. FINLAND ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 224. FINLAND ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 225. FINLAND ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 226. FINLAND ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 227. FINLAND ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 228. FRANCE ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 229. FRANCE ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 230. FRANCE ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 231. FRANCE ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 232. FRANCE ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 233. FRANCE ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 234. FRANCE ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 235. FRANCE ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 236. GERMANY ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 237. GERMANY ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 238. GERMANY ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 239. GERMANY ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 240. GERMANY ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 241. GERMANY ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 242. GERMANY ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 243. GERMANY ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 244. ISRAEL ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 245. ISRAEL ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 246. ISRAEL ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 247. ISRAEL ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 248. ISRAEL ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 249. ISRAEL ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 250. ISRAEL ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 251. ISRAEL ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 252. ITALY ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 253. ITALY ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 254. ITALY ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 255. ITALY ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 256. ITALY ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 257. ITALY ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 258. ITALY ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 259. ITALY ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 260. NETHERLANDS ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 261. NETHERLANDS ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 262. NETHERLANDS ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 263. NETHERLANDS ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 264. NETHERLANDS ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 265. NETHERLANDS ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 266. NETHERLANDS ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 267. NETHERLANDS ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 268. NIGERIA ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 269. NIGERIA ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 270. NIGERIA ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 271. NIGERIA ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 272. NIGERIA ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 273. NIGERIA ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 274. NIGERIA ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 275. NIGERIA ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 276. NORWAY ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 277. NORWAY ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 278. NORWAY ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 279. NORWAY ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 280. NORWAY ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 281. NORWAY ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 282. NORWAY ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 283. NORWAY ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 284. POLAND ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 285. POLAND ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 286. POLAND ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 287. POLAND ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 288. POLAND ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 289. POLAND ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 290. POLAND ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 291. POLAND ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 292. QATAR ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 293. QATAR ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 294. QATAR ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 295. QATAR ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 296. QATAR ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 297. QATAR ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 298. QATAR ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 299. QATAR ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 300. RUSSIA ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 301. RUSSIA ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 302. RUSSIA ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 303. RUSSIA ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 304. RUSSIA ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 305. RUSSIA ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 306. RUSSIA ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 307. RUSSIA ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 308. SAUDI ARABIA ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 309. SAUDI ARABIA ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 310. SAUDI ARABIA ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 311. SAUDI ARABIA ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 312. SAUDI ARABIA ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 313. SAUDI ARABIA ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 314. SAUDI ARABIA ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 315. SAUDI ARABIA ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 316. SOUTH AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 317. SOUTH AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 318. SOUTH AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 319. SOUTH AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 320. SOUTH AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 321. SOUTH AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 322. SOUTH AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 323. SOUTH AFRICA ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 324. SPAIN ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 325. SPAIN ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 326. SPAIN ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 327. SPAIN ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 328. SPAIN ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 329. SPAIN ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 330. SPAIN ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 331. SPAIN ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 332. SWEDEN ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 333. SWEDEN ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 334. SWEDEN ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 335. SWEDEN ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 336. SWEDEN ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 337. SWEDEN ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 338. SWEDEN ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 339. SWEDEN ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 340. SWITZERLAND ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 341. SWITZERLAND ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 342. SWITZERLAND ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 343. SWITZERLAND ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 344. SWITZERLAND ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 345. SWITZERLAND ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 346. SWITZERLAND ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 347. SWITZERLAND ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 348. TURKEY ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 349. TURKEY ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 350. TURKEY ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 351. TURKEY ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 352. TURKEY ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 353. TURKEY ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 354. TURKEY ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 355. TURKEY ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 356. UNITED ARAB EMIRATES ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 357. UNITED ARAB EMIRATES ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 358. UNITED ARAB EMIRATES ANTIFUNGAL DRUGS MARKET SIZE, BY ALLYLAMINES, 2018-2030 (USD MILLION)
  • TABLE 359. UNITED ARAB EMIRATES ANTIFUNGAL DRUGS MARKET SIZE, BY AZOLES, 2018-2030 (USD MILLION)
  • TABLE 360. UNITED ARAB EMIRATES ANTIFUNGAL DRUGS MARKET SIZE, BY ECHINOCANDINS, 2018-2030 (USD MILLION)
  • TABLE 361. UNITED ARAB EMIRATES ANTIFUNGAL DRUGS MARKET SIZE, BY POLYENES, 2018-2030 (USD MILLION)
  • TABLE 362. UNITED ARAB EMIRATES ANTIFUNGAL DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 363. UNITED ARAB EMIRATES ANTIFUNGAL DRUGS MARKET SIZE, BY THERAPEUTIC INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 364. UNITED KINGDOM ANTIFUNGAL DRUGS MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 365. UNITED KINGDOM ANTIFUNGAL DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MI